CDKN2A and renal cell carcinoma: Taking into account the different studies related to diagnosis in PrCa, BdCa, and RCC, hypermethylation of RASSF1A, APC, RARB2, and ARF [111,112] seem to be the most consolidated biomarkers to use in plasma, serum, and/or urine.